Frankfurt - Delayed Quote EUR
Diamyd Medical AB (publ) (DMN.F)
0.6740
+0.0180
+(2.74%)
As of 9:16:57 AM GMT+2. Market Open.
Breakdown
TTM
8/31/2024
8/31/2023
8/31/2022
8/31/2021
Total Revenue
182
130
546
454
253
Cost of Revenue
3,938
3,710
3,634
4,403
2,501
Gross Profit
-3,756
-3,580
-3,088
-3,949
-2,248
Operating Expense
172,447
143,694
112,758
110,987
83,633
Operating Income
-176,203
-147,274
-115,846
-114,936
-85,881
Net Non Operating Interest Income Expense
4,170
3,745
1,048
8,006
1,512
Pretax Income
-170,847
-151,850
-116,073
-103,516
60,045
Net Income Common Stockholders
-170,847
-151,850
-116,073
-103,517
60,046
Diluted NI Available to Com Stockholders
-170,847
-151,850
-116,073
-103,517
60,046
Basic EPS
-1.69
-1.59
-1.49
-1.36
0.87
Diluted EPS
-1.69
-1.59
-1.49
-1.36
0.87
Basic Average Shares
101,141.3520
95,154.0750
78,650.4940
78,749.9500
71,818.4050
Diluted Average Shares
101,141.3520
95,154.0750
78,650.4940
78,749.9500
71,818.4050
Total Operating Income as Reported
-173,200
-146,567
-120,806
-118,176
-85,880
Total Expenses
176,385
147,404
116,392
115,390
86,134
Net Income from Continuing & Discontinued Operation
-170,847
-151,850
-116,073
-103,517
60,046
Normalized Income
-163,503
-137,295
-116,073
-110,170
-84,368
Interest Income
4,969
3,753
1,051
8,259
1,965
Interest Expense
799
8
3
253
453
Net Interest Income
4,170
3,745
1,048
8,006
1,512
EBIT
-170,048
-151,842
-116,070
-103,263
60,498
EBITDA
-158,514
-140,851
-111,201
-98,880
61,280
Reconciled Cost of Revenue
3,938
3,710
3,634
4,403
2,501
Reconciled Depreciation
11,534
10,991
4,869
4,383
782
Net Income from Continuing Operation Net Minority Interest
-170,847
-151,850
-116,073
-103,517
60,046
Total Unusual Items Excluding Goodwill
-7,344
-14,555
--
6,653
144,414
Total Unusual Items
-7,344
-14,555
--
6,653
144,414
Normalized EBITDA
-151,170
-126,296
-111,201
-105,533
-83,134
8/31/2021 - 8/28/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SLNCF Silence Therapeutics plc
0.9500
0.00%
MOLN Molecular Partners AG
3.8900
-8.47%
PCSA Processa Pharmaceuticals, Inc.
0.2392
+8.97%
LPTX Leap Therapeutics, Inc.
0.3950
+2.33%
ADIL Adial Pharmaceuticals, Inc.
0.7001
+3.29%
CRVS Corvus Pharmaceuticals, Inc.
3.5200
+5.71%
VTVT vTv Therapeutics Inc.
20.55
+3.32%
SPRC SciSparc Ltd.
0.2869
+4.48%
MLEC Moolec Science SA
0.6145
-9.65%
OSRH OSR Holdings, Inc.
1.3700
+2.24%